These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R mBio; 2017 Sep; 8(5):. PubMed ID: 28928215 [TBL] [Abstract][Full Text] [Related]
66. The Multifaceted B Cell Response to Influenza Virus. Lam JH; Baumgarth N J Immunol; 2019 Jan; 202(2):351-359. PubMed ID: 30617116 [TBL] [Abstract][Full Text] [Related]
67. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186 [TBL] [Abstract][Full Text] [Related]
68. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine. Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124 [TBL] [Abstract][Full Text] [Related]
69. Novel Approaches for The Development of Live Attenuated Influenza Vaccines. Blanco-Lobo P; Nogales A; Rodríguez L; Martínez-Sobrido L Viruses; 2019 Feb; 11(2):. PubMed ID: 30813325 [TBL] [Abstract][Full Text] [Related]
70. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848 [TBL] [Abstract][Full Text] [Related]
71. The coming era of quadrivalent human influenza vaccines: who will benefit? Barr IG; Jelley LL Drugs; 2012 Dec; 72(17):2177-85. PubMed ID: 23110610 [TBL] [Abstract][Full Text] [Related]
72. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710 [TBL] [Abstract][Full Text] [Related]
73. Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996-2012: Implications for vaccine composition strategy. Paiva TM; Benega MA; Silva DB; Santos KC; Cruz AS; Hortenci MF; Barbieri MT; Monteiro MM; Barbosa HA; Carvalhanas TR J Med Virol; 2013 Nov; 85(11):1983-9. PubMed ID: 23926069 [TBL] [Abstract][Full Text] [Related]
74. N-Linked Glycans and K147 Residue on Hemagglutinin Synergize To Elicit Broadly Reactive H1N1 Influenza Virus Antibodies. Huang Y; Owino SO; Crevar CJ; Carter DM; Ross TM J Virol; 2020 Feb; 94(6):. PubMed ID: 31852790 [TBL] [Abstract][Full Text] [Related]
75. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults. Song JY; Lee J; Woo HJ; Wie SH; Lee JS; Kim SW; Kim TH; Jung SI; Noh JY; Choi WS; Cheong HJ; Kim WJ Hum Vaccin Immunother; 2019; 15(3):710-716. PubMed ID: 30396317 [TBL] [Abstract][Full Text] [Related]
76. [Influenza season 2007/'08 in the Netherlands: antigenic variation, oseltamivir resistance and vaccine composition for the 2008/'09 season]. Rimmelzwaan GF; de Jong JC; Donker GA; Meijer A; Fouchier RA; Osterhaus AD Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2138-44. PubMed ID: 18856032 [TBL] [Abstract][Full Text] [Related]
78. Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness. Eichelberger MC; Morens DM; Taubenberger JK Curr Opin Immunol; 2018 Aug; 53():38-44. PubMed ID: 29674167 [TBL] [Abstract][Full Text] [Related]
79. Novel Platforms for the Development of a Universal Influenza Vaccine. Kumar A; Meldgaard TS; Bertholet S Front Immunol; 2018; 9():600. PubMed ID: 29628926 [TBL] [Abstract][Full Text] [Related]
80. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines. Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A Front Immunol; 2018; 9():2312. PubMed ID: 30356772 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]